Caribou Biosciences, Inc.
Price
Where the revenue goes
Loading the income statement flow…
Where the revenue comes from
Fundamentals
Loading key figures…
Insiders, analysts and people
All trades and changesLoading insiders, analysts and opinions…
Co se právě děje
AI souhrnAbout the company
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
- Website
- cariboubio.com
- Employees
- 97
- Country
- United States
- Fiscal year end
- 31. 12.
- Data since
- 23. 7. 2021